All In Biotech

Drug Trial Radar · NCT03901092

A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation

A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 PET Scan Interpretation

Last checked: Nov 20, 2026Latest source record: Sep 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

242

Actual

Start

Mar 26, 2019

Primary completion

Apr 26, 2019

Study completion Apr 26, 2019

Sponsor

Lead sponsor
Avid RadiopharmaceuticalsIndustry
Sponsor type
Industry
First posted
Apr 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the performance of physician readers trained to read flortaucipir-PET (positron emission tomography) scans.

Conditions

  • Alzheimer Disease

Interventions

  • flortaucipir F 18Drug

    No study drug will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Objective 1 Analysis 1: Diagnostic Performance of Individual Readers (NFT Score)Time frame: baseline scan
  2. Primary Objective 1 Analysis 2: Diagnostic Performance of Individual Readers (NIA-AA Autopsy Diagnosis)Time frame: baseline scan
  3. Primary Objective 2: Inter-reader Reliability of Reader Interpretation of Flortaucipir-PET ImagingTime frame: baseline scan

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • American College of Radiology

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.